LICENSE AGREEMENT between G1 THERAPEUTICS, INC. and EQRX, INC. DATED July 22, 2020License Agreement • October 29th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made as of July 22, 2020 (the “Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (“G1”), having a place of business at 700 Park Offices Drive, Suite 200, Research Triangle Park, NC 27709, and EQRx, Inc., a Delaware corporation (“Licensee”), having a place of business at 50 Hampshire St., Cambridge, MA 02139. G1 and Licensee may be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIALExclusive License Agreement • October 29th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of April 1, 2020 (the “Effective Date”) by and among LYNK PHARMACEUTICAL (HANGZHOU) CO., LTD, a Chinese corporation having its principal place of business at 291 Fucheng Road, Bldg 5-402, Jiangan, Hangzhou, Zhejiang 310018, China (“Lynk”), and EQRX, INC., a Delaware corporation having its principal place of business at 50 Hampshire St., Cambridge, MA 02139 (“EQRx”). Lynk and EQRx are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
